a trend toward significancep = 0.04
The on-treatment HBeAg seroconversion in these patients showed a trend toward significance, with 71.4% (5 out of 7) in the MASLD-CHB group compared to 44.9% (40 out of 89) in the CHB non-MASLD group ( p = 0.04).
The on-treatment HBeAg seroconversion in these patients showed a trend toward significance, with 71.4% (5 out of 7) in the MASLD-CHB group compared to 44.9% (40 out of 89) in the CHB non-MASLD group ( p = 0.04).
The on-treatment HBeAg seroconversion in these patients showed a trend toward significance, with 71.4% (5 out of 7) in the MASLD-CHB group compared to 44.9% (40 out of 89) in the CHB non-MASLD group ( p = 0.04).
For cirrhosis predictors, variables with significance at p < 0.05 or a notable trend at p < 0.1 were included in the multiple multivariate logistic regression model.